{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:26:20Z","timestamp":1791530780555,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Synaptic dysfunction is increasingly recognized as a core feature of psychiatric disorders, yet fluid biomarkers that reflect such changes in vivo are lacking. Here, we applied targeted mass spectrometry to quantify low-abundant synaptic proteins in cerebrospinal fluid from 672 individuals with anorexia nervosa, attention-deficit\/hyperactivity disorder (ADHD), bipolar disorder (BD), schizophrenia spectrum disorders (SCZ\u2009+\u2009), and healthy controls. Synaptic protein levels were markedly reduced in SCZ\u2009+\u2009, with intermediate reductions in BD and ADHD. Using a data-driven approach to model transdiagnostic contrasts\u2014psychotic experience, cognitive and functional impairment\u2014a shared two-biomarker signature emerged: elevated LAMP1, a phagolysosomal marker, and reduced NPTX2, a synaptic activity marker which inhibits complement-dependent synapse elimination. Combining this ratio with polygenic scores improved diagnostic classification. Key findings were extended to an independent cohort at first-episode psychosis. These results support synaptic pathology as a measurable and transdiagnostic feature across several psychiatric disorders and highlight the potential of integrating fluid and genetic biomarkers.<\/jats:p>","DOI":"10.1038\/s41467-026-76187-y","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:04:57Z","timestamp":1785405897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cerebrospinal fluid biomarkers reveal transdiagnostic synaptic dysfunction across major psychiatric disorders"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-6054","authenticated-orcid":false,"given":"Andreas","family":"G\u00f6teson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2856-6060","authenticated-orcid":false,"given":"Johanna","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1044-0192","authenticated-orcid":false,"given":"Elena","family":"Camporesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Luisa","family":"Klahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"H\u00f6rbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sigstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timea","family":"Sparding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"P\u00e5lsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurimantas","family":"Pelanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneli","family":"Goulding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniella","family":"Isgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-5250","authenticated-orcid":false,"given":"Sophie","family":"Erhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cervenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-3264","authenticated-orcid":false,"given":"Cynthia M.","family":"Bulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-2785","authenticated-orcid":false,"given":"Carl M.","family":"Sellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7396-3233","authenticated-orcid":false,"given":"Ann","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4496-6451","authenticated-orcid":false,"given":"Mikael","family":"Land\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"76187_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0022-3956(82)90038-3","volume":"17","author":"I Feinberg","year":"1982","unstructured":"Feinberg, I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J. Psychiatr. Res. 17, 319\u2013334 (1982).","journal-title":"J. Psychiatr. Res."},{"key":"76187_CR2","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41380-023-02043-w","volume":"28","author":"OD Howes","year":"2023","unstructured":"Howes, O. D. & Onwordi, E. C. The synaptic hypothesis of schizophrenia version III: a master mechanism. Mol. Psychiatry 28, 1843\u20131856 (2023).","journal-title":"Mol. Psychiatry"},{"key":"76187_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","volume":"604","author":"T Singh","year":"2022","unstructured":"Singh, T. et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604, 509\u2013516 (2022).","journal-title":"Nature"},{"key":"76187_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","volume":"604","author":"V Trubetskoy","year":"2022","unstructured":"Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 604, 502\u2013508 (2022).","journal-title":"Nature"},{"key":"76187_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41593-018-0334-7","volume":"22","author":"CM Sellgren","year":"2019","unstructured":"Sellgren, C. M. et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat. Neurosci. 22, 374\u2013385 (2019).","journal-title":"Nat. Neurosci."},{"key":"76187_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.biopsych.2023.05.022","volume":"95","author":"EC Onwordi","year":"2024","unstructured":"Onwordi, E. C. et al. Synaptic terminal density early in the course of schizophrenia: an in vivo UCB-J positron emission tomographic imaging study of SV2A. Biol. Psychiatry 95, 639\u2013646 (2024).","journal-title":"Biol. Psychiatry"},{"key":"76187_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpsychires.2023.02.026","volume":"161","author":"JH Yoon","year":"2023","unstructured":"Yoon, J. H. et al. Reductions in synaptic marker SV2A in early-course Schizophrenia. J. Psychiatr. Res. 161, 213\u2013217 (2023).","journal-title":"J. Psychiatr. Res."},{"key":"76187_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jamapsychiatry.2024.3608","volume":"82","author":"MB Blasco","year":"2025","unstructured":"Blasco, M. B. et al. Synaptic density in early stages of psychosis and clinical high risk. JAMA Psychiatry 82, 171\u2013180 (2025).","journal-title":"JAMA Psychiatry"},{"key":"76187_CR9","doi-asserted-by":"publisher","first-page":"eabf6935","DOI":"10.1126\/sciadv.abf6935","volume":"7","author":"M-F Xiao","year":"2021","unstructured":"Xiao, M.-F. et al. A biomarker-authenticated model of schizophrenia implicating NPTX2 loss of function. Sci. Adv. 7, eabf6935 (2021).","journal-title":"Sci. Adv."},{"key":"76187_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/pcn.13848","volume":"79","author":"S Hidese","year":"2025","unstructured":"Hidese, S. et al. Cerebrospinal fluid neuromarker levels in patients with schizophrenia: a multiplex immunoassay study with a large sample. Psychiatry Clin. Neurosci. 79, 488\u2013495 (2025).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"76187_CR11","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1038\/s41380-021-01184-0","volume":"26","author":"R Radhakrishnan","year":"2021","unstructured":"Radhakrishnan, R. et al. In vivo evidence of lower synaptic vesicle density in schizophrenia. Mol. Psychiatry 26, 7690\u20137698 (2021).","journal-title":"Mol. Psychiatry"},{"key":"76187_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14122-0","volume":"11","author":"EC Onwordi","year":"2020","unstructured":"Onwordi, E. C. et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat. Commun. 11, 246 (2020).","journal-title":"Nat. Commun."},{"key":"76187_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0924-977X(98)00042-X","volume":"9","author":"M Land\u00e9n","year":"1999","unstructured":"Land\u00e9n, M. et al. Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 9, 311\u2013315 (1999).","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"76187_CR14","doi-asserted-by":"publisher","first-page":"eaat8127","DOI":"10.1126\/science.aat8127","volume":"362","author":"MJ Gandal","year":"2018","unstructured":"Gandal, M. J. et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 362, eaat8127 (2018).","journal-title":"Science"},{"key":"76187_CR15","doi-asserted-by":"publisher","first-page":"112497","DOI":"10.1016\/j.celrep.2023.112497","volume":"42","author":"S Aryal","year":"2023","unstructured":"Aryal, S. et al. Deep proteomics identifies shared molecular pathway alterations in synapses of patients with schizophrenia and bipolar disorder and mouse model. Cell Rep. 42, 112497 (2023).","journal-title":"Cell Rep."},{"key":"76187_CR16","doi-asserted-by":"publisher","first-page":"eadg5136","DOI":"10.1126\/science.adg5136","volume":"384","author":"WB Ruzicka","year":"2024","unstructured":"Ruzicka, W. B. et al. Single-cell multi-cohort dissection of the schizophrenia transcriptome. Science 384, eadg5136 (2024).","journal-title":"Science"},{"key":"76187_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41380-018-0041-5","volume":"24","author":"EF Osimo","year":"2019","unstructured":"Osimo, E. F., Beck, K., Reis Marques, T. & Howes, O. D. Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Mol. Psychiatry 24, 549\u2013561 (2019).","journal-title":"Mol. Psychiatry"},{"key":"76187_CR18","first-page":"374","volume":"46","author":"A Berdenis van Berlekom","year":"2020","unstructured":"Berdenis van Berlekom, A. et al. Synapse pathology in schizophrenia: a meta-analysis of postsynaptic elements in postmortem brain studies. Schizophr. Bull. 46, 374\u2013386 (2020).","journal-title":"Schizophr. Bull."},{"key":"76187_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41386-020-00949-5","volume":"46","author":"N Akula","year":"2021","unstructured":"Akula, N. et al. Deep transcriptome sequencing of subgenual anterior cingulate cortex reveals cross-diagnostic and diagnosis-specific RNA expression changes in major psychiatric disorders. Neuropsychopharmacology 46, 1364\u20131372 (2021).","journal-title":"Neuropsychopharmacology"},{"key":"76187_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41593-022-01024-6","volume":"25","author":"PP Zandi","year":"2022","unstructured":"Zandi, P. P. et al. Amygdala and anterior cingulate transcriptomes from individuals with bipolar disorder reveal downregulated neuroimmune and synaptic pathways. Nat. Neurosci. 25, 381\u2013389 (2022).","journal-title":"Nat. Neurosci."},{"key":"76187_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-022-01285-8","volume":"55","author":"D Demontis","year":"2023","unstructured":"Demontis, D. et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat. Genet. 55, 198\u2013208 (2023).","journal-title":"Nat. Genet."},{"key":"76187_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.cell.2024.12.002","volume":"188","author":"MJ Adams","year":"2025","unstructured":"Adams, M. J. et al. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell 188, 640\u2013652.e9 (2025).","journal-title":"Cell"},{"key":"76187_CR23","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41586-024-08468-9","volume":"639","author":"KS O\u2019Connell","year":"2025","unstructured":"O\u2019Connell, K. S. et al. Genomics yields biological and phenotypic insights into bipolar disorder. Nature 639, 968\u2013975 (2025).","journal-title":"Nature"},{"key":"76187_CR24","doi-asserted-by":"publisher","unstructured":"G\u00f6teson, A. et al. Mapping the cerebrospinal fluid proteome in bipolar disorder. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2025.01.007 (2025).","DOI":"10.1016\/j.biopsych.2025.01.007"},{"key":"76187_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jpsychires.2022.10.010","volume":"156","author":"N G\u00f3mez de San Jos\u00e9","year":"2022","unstructured":"G\u00f3mez de San Jos\u00e9, N. et al. Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders. J. Psychiatr. Res. 156, 390\u2013397 (2022).","journal-title":"J. Psychiatr. Res."},{"key":"76187_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-0825-7","volume":"10","author":"MR Al Shweiki","year":"2020","unstructured":"Al Shweiki, M. R. et al. Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. Transl. Psychiatry 10, 1\u201312 (2020).","journal-title":"Transl. Psychiatry"},{"key":"76187_CR27","doi-asserted-by":"publisher","first-page":"e301752","DOI":"10.1136\/bmjment-2025-301752","volume":"28","author":"P Steinacker","year":"2025","unstructured":"Steinacker, P. et al. Evidence for reduced synaptic protein SNAP-25 in cerebrospinal fluid in major depressive disorder and schizophrenia. BMJ Ment. Health 28, e301752 (2025).","journal-title":"BMJ Ment. Health"},{"key":"76187_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm, A. et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol. Neurodegener. 9, 53 (2014).","journal-title":"Mol. Neurodegener."},{"key":"76187_CR29","first-page":"e12179","volume":"13","author":"J Nilsson","year":"2021","unstructured":"Nilsson, J. et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer\u2019s disease. Alzheimers Dement. Diagn. Assess. Dis. Monit. 13, e12179 (2021).","journal-title":"Alzheimers Dement. Diagn. Assess. Dis. Monit."},{"key":"76187_CR30","doi-asserted-by":"publisher","first-page":"103793","DOI":"10.1016\/j.ebiom.2021.103793","volume":"75","author":"E Camporesi","year":"2022","unstructured":"Camporesi, E. et al. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. eBioMedicine 75, 103793 (2022).","journal-title":"eBioMedicine"},{"key":"76187_CR31","doi-asserted-by":"publisher","first-page":"e0206478","DOI":"10.1371\/journal.pone.0206478","volume":"13","author":"LM Schilde","year":"2018","unstructured":"Schilde, L. M. et al. Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research. PLoS ONE 13, e0206478 (2018).","journal-title":"PLoS ONE"},{"key":"76187_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47971-5","volume":"15","author":"L Karlsson","year":"2024","unstructured":"Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. Nat. Commun. 15, 3676 (2024).","journal-title":"Nat. Commun."},{"key":"76187_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83281-y","volume":"15","author":"S Mravinacov\u00e1","year":"2025","unstructured":"Mravinacov\u00e1, S. et al. Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases. Sci. Rep. 15, 668 (2025).","journal-title":"Sci. Rep."},{"key":"76187_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41588-023-01300-6","volume":"55","author":"N De Klein","year":"2023","unstructured":"De Klein, N. et al. Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases. Nat. Genet. 55, 377\u2013388 (2023).","journal-title":"Nat. Genet."},{"key":"76187_CR35","doi-asserted-by":"publisher","first-page":"7446","DOI":"10.1038\/s41380-021-01236-5","volume":"26","author":"A G\u00f6teson","year":"2021","unstructured":"G\u00f6teson, A. et al. Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder. Mol. Psychiatry 26, 7446\u20137453 (2021).","journal-title":"Mol. Psychiatry"},{"key":"76187_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson, J. F., Svedberg, P., Ol\u00e9n, O., Bruze, G. & Neovius, M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur. J. Epidemiol. 34, 423\u2013437 (2019).","journal-title":"Eur. J. Epidemiol."},{"key":"76187_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33797-6","volume":"13","author":"J Gracias","year":"2022","unstructured":"Gracias, J. et al. Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia. Nat. Commun. 13, 6427 (2022).","journal-title":"Nat. Commun."},{"key":"76187_CR38","doi-asserted-by":"publisher","first-page":"eadm9654","DOI":"10.1126\/scitranslmed.adm9654","volume":"17","author":"A Sogorb-Esteve","year":"2025","unstructured":"Sogorb-Esteve, A. et al. Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes. Sci. Transl. Med. 17, eadm9654 (2025).","journal-title":"Sci. Transl. Med."},{"key":"76187_CR39","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035\u20131048 (2019).","journal-title":"JAMA Neurol."},{"key":"76187_CR40","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/nn.2621","volume":"13","author":"MC Chang","year":"2010","unstructured":"Chang, M. C. et al. Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons. Nat. Neurosci. 13, 1090\u20131097 (2010).","journal-title":"Nat. Neurosci."},{"key":"76187_CR41","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.neuron.2015.02.020","volume":"85","author":"KA Pelkey","year":"2015","unstructured":"Pelkey, K. A. et al. Pentraxins coordinate excitatory synapse maturation and circuit integration of parvalbumin interneurons. Neuron 85, 1257\u20131272 (2015).","journal-title":"Neuron"},{"key":"76187_CR42","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1523\/JNEUROSCI.2768-16.2016","volume":"37","author":"S-J Lee","year":"2017","unstructured":"Lee, S.-J. et al. Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses. J. Neurosci. 37, 1062\u20131080 (2017).","journal-title":"J. Neurosci."},{"key":"76187_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.biopsych.2022.06.017","volume":"92","author":"OD Howes","year":"2022","unstructured":"Howes, O. D. & Shatalina, E. Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance. Biol. Psychiatry 92, 501\u2013513 (2022).","journal-title":"Biol. Psychiatry"},{"key":"76187_CR44","doi-asserted-by":"publisher","first-page":"eadf0141","DOI":"10.1126\/scitranslmed.adf0141","volume":"15","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci. Transl. Med. 15, eadf0141 (2023).","journal-title":"Sci. Transl. Med."},{"key":"76187_CR45","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/brain\/awae032","volume":"147","author":"J Nilsson","year":"2024","unstructured":"Nilsson, J. et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain 147, 2414\u20132427 (2024).","journal-title":"Brain"},{"key":"76187_CR46","doi-asserted-by":"publisher","unstructured":"Oh, H. S.-H. et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer\u2019s disease. Nat. Med. 1\u201312 https:\/\/doi.org\/10.1038\/s41591-025-03565-2 (2025).","DOI":"10.1038\/s41591-025-03565-2"},{"key":"76187_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-020-00388-2","volume":"15","author":"I van Steenoven","year":"2020","unstructured":"van Steenoven, I. et al. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Mol. Neurodegener. 15, 36 (2020).","journal-title":"Mol. Neurodegener."},{"key":"76187_CR48","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.cell.2016.04.001","volume":"165","author":"H Lui","year":"2016","unstructured":"Lui, H. et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 165, 921\u2013935 (2016).","journal-title":"Cell"},{"key":"76187_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000543335","volume":"84","author":"M Land\u00e9n","year":"2025","unstructured":"Land\u00e9n, M. et al. The St. G\u00f6ran project: a multipronged strategy for longitudinal studies for bipolar disorders. Neuropsychobiology 84, 86\u201399 (2025).","journal-title":"Neuropsychobiology"},{"key":"76187_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cct.2018.09.015","volume":"74","author":"LM Thornton","year":"2018","unstructured":"Thornton, L. M. et al. The Anorexia Nervosa Genetics Initiative (ANGI): overview and methods. Contemp. Clin. Trials 74, 61\u201369 (2018).","journal-title":"Contemp. Clin. Trials"},{"key":"76187_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-018-0339-1","volume":"10","author":"L Gaetani","year":"2018","unstructured":"Gaetani, L. et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res. Ther. 10, 8 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"76187_CR52","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/npp.2012.231","volume":"38","author":"J Jakobsson","year":"2013","unstructured":"Jakobsson, J. et al. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology 38, 664\u2013672 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"76187_CR53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712\u2013716 (2016).","journal-title":"Science"},{"key":"76187_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.bbrc.2018.02.131","volume":"497","author":"T Ishii","year":"2018","unstructured":"Ishii, T. et al. Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. Biochem. Biophys. Res. Commun. 497, 683\u2013688 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"76187_CR55","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.20230073","volume":"181","author":"L Jonsson","year":"2024","unstructured":"Jonsson, L. et al. Association of occupational dysfunction and hospital admissions with different polygenic profiles in bipolar disorder. Am. J. Psychiatry 181, 620\u2013629 (2024).","journal-title":"Am. J. Psychiatry"},{"key":"76187_CR56","doi-asserted-by":"publisher","unstructured":"G\u00f6teson, A. et al. Cerebrospinal fluid biomarkers reveal transdiagnostic synaptic dysfunction across major psychiatric disorders, https:\/\/github.com\/andreasgoteson\/2025-CSF-synaptic-biomarkers-major-psychiatric-disorders, https:\/\/doi.org\/10.5281\/zenodo.21332816, 2026.","DOI":"10.5281\/zenodo.21332816"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76187-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76187-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76187-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:06:11Z","timestamp":1785452771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76187-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76187"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76187-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.S. has served on the scientific advisory board for Otsuka Pharma AB, Teva Pharmaceuticals, and Outermost Therapeutics (outside submitted work). H.Z. has served on scientific advisory boards and\/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has during 2023-2025 served as a consultant, at advisory boards, and has given lectures, produced educational materials and participated in educational programs for AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Eisai, Lilly, Neurimmune, Novartis, Roche Diagnostics, Sunbird Bio, and Siemens Healthineers; all before Sept 2025, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Program, outside the work presented in this paper. Since Sept 2025, KB is an employee of Lilly and has no other disclosures. All other authors report no biomedical financial interests or potential conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7604"}}